Focus: Galt Pharmaceuticals is a specialty pharmaceutical company headquartered in Atlanta focused on diagnostics and small-molecule therapeutics in musculoskeletal and neurology indications. The company operates primarily as a generics/legacy product manager with minimal pipeline activity.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Hot — 128 jobs added in 30d
Net +128 (128 new, 0 removed). Aggressive expansion phase.
Galt is a low-growth, legacy-asset manager suitable only for stable commercial/operations roles; unsuitable for scientists or those seeking innovation or long-term career expansion.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company's sole revenue driver, a generic ANDA with 100% revenue concentration risk; limited growth prospects.
Help build intelligence for Galt Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Galt Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA-originated product nearing loss of exclusivity; represents near-term revenue cliff without identified successor.
Scheduled benzodiazepine approaching 2028 LOE; limited differentiation in crowded sleep market.
Legacy generic formulation; minimal revenue contribution relative to ORPHENGESIC FORTE.
1 discontinued, 1 duplicate formulations not shown
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles